Furthermore, researchers identified LOX expression was significantly increased in recurrent osteosarcoma CAFs compared to primary osteosarcoma, and targeting LOX of CAFs is an effective treatment for recurrent osteosarcoma [47]. The gene discussed is LOX; the disease is osteosarcoma.